Chemours (NYSE:CC) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Chemours (NYSE:CC) posted its quarterly earnings data on Thursday. The specialty chemicals company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.04), FiscalAI reports. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The firm had revenue of $1.50 billion during the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter in the prior year, the firm posted $0.40 EPS. Chemours’s quarterly revenue was down .9% compared to the same quarter last year. Chemours updated its Q4 2025 guidance to EPS and its FY 2025 guidance to EPS.

Chemours Stock Down 2.3%

Shares of CC traded down $0.28 during mid-day trading on Thursday, reaching $11.77. The company’s stock had a trading volume of 3,956,399 shares, compared to its average volume of 2,962,959. Chemours has a 12-month low of $9.13 and a 12-month high of $22.38. The stock has a market cap of $1.76 billion, a PE ratio of -4.20 and a beta of 1.64. The company has a debt-to-equity ratio of 17.16, a current ratio of 1.68 and a quick ratio of 0.83. The company’s 50 day moving average is $14.94 and its 200 day moving average is $13.21.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 15th. Stockholders of record on Friday, November 14th will be issued a $0.0875 dividend. The ex-dividend date is Friday, November 14th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 3.0%. Chemours’s dividend payout ratio is presently -12.50%.

Insider Activity at Chemours

In other Chemours news, CEO Denise Dignam acquired 4,068 shares of the company’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $12.06 per share, for a total transaction of $49,060.08. Following the acquisition, the chief executive officer owned 191,546 shares in the company, valued at $2,310,044.76. The trade was a 2.17% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.47% of the company’s stock.

Institutional Trading of Chemours

A number of large investors have recently made changes to their positions in CC. Baird Financial Group Inc. acquired a new stake in shares of Chemours in the 1st quarter valued at about $148,000. Royal Bank of Canada boosted its position in shares of Chemours by 6.8% in the 1st quarter. Royal Bank of Canada now owns 585,702 shares of the specialty chemicals company’s stock valued at $7,926,000 after purchasing an additional 37,382 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Chemours in the 1st quarter valued at about $161,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Chemours by 149.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,243 shares of the specialty chemicals company’s stock valued at $593,000 after purchasing an additional 25,899 shares during the period. Finally, Empowered Funds LLC acquired a new stake in shares of Chemours in the 1st quarter valued at about $403,000. 76.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on CC shares. UBS Group upped their price target on Chemours from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Truist Financial upped their price target on Chemours from $18.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, September 16th. Royal Bank Of Canada set a $19.00 price target on Chemours and gave the stock an “outperform” rating in a report on Tuesday, October 14th. Mizuho cut their price target on Chemours from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, October 16th. Finally, Zacks Research downgraded Chemours from a “hold” rating to a “strong sell” rating in a report on Friday, October 17th. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Chemours currently has an average rating of “Hold” and a consensus target price of $18.50.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.